The central role of dysregulated kinase activity in the etiology of progressive disorders,
including cancer, has fostered incremental efforts on drug discovery programs over the past …

Chronic myeloid leukemia (CML), caused by constitutively active BCR-ABL1 fusion tyrosine
kinase, has served as a paradigm for successful application of molecularly targeted cancer …

Background Asciminib is an allosteric inhibitor that binds a myristoyl site of the BCR-ABL1
protein, locking BCR-ABL1 into an inactive conformation through a mechanism distinct from …

The successful treatment of cancer has significantly improved as a result of targeted therapy
and immunotherapy. However, during chemotherapy, cancer cells evolve and can acquire …

Anthracycline chemotherapy maintains a prominent role in treating many forms of cancer.
Cardiotoxic side effects limit their dosing and improved cancer outcomes expose the cancer …

Acute Lymphoblastic Leukemia in Children | New England Journal of Medicine Skip to main
content The New England Journal of Medicine homepage Advanced Search SEARCH …

Drug resistance is a major challenge in cancer treatment. Emerging evidence indicates that
deregulation of YAP/TAZ signaling may be a major mechanism of intrinsic and acquired …

CRISPR/Cas9 has become a powerful method for making changes to the genome of many
organisms. First discovered in bacteria as part of an adaptive immune system …

Pancreatic ductal adenocarcinoma (PDAC) is one of the deadliest cancers in western
countries, with a median survival of 6 months and an extremely low percentage of long-term …

With the emergence of genomic profiling technologies and selective molecular targeted
therapies, biomarkers play an increasingly important role in the clinical management of …